Intercept Pharmaceuticals CMO David Shapiro Unloads 4,928 Shares (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) CMO David Shapiro sold 4,928 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $71.85, for a total value of $354,076.80. Following the transaction, the chief marketing officer now directly owns 8,663 shares of the company’s stock, valued at approximately $622,437. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $1.14. During the same quarter last year, the company posted ($1.86) earnings per share.
A number of research firms have recently commented on ICPT. Analysts at Janney Montgomery Scott raised their price target on shares of Intercept Pharmaceuticals to $300.00 in a research note to investors on Friday. Separately, analysts at Needham & Company raised their price target on shares of Intercept Pharmaceuticals from $55.00 to $320.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Oppenheimer raised their price target on shares of Intercept Pharmaceuticals from $94.00 to $360.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of “Buy” and an average price target of $369.86.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.